Partner Headlines - BMY

  1. Trending on Dividend.com: Bristol-Myers Disappoints and DHT Surprises, ...

    Dividend.com
  2. 3 Big Drugmakers That Beat Wall Street Q2 Estimates Thursday

    Investors Business Daily
  3. Amazon, Alphabet, Baidu, Ford, Celgene On Tap Thursday

    Investors Business Daily
  4. Investing Action Plan: Amazon, Alphabet, Baidu, Ford, Celgene

    Investors Business Daily
  5. Investing Action Plan: Apple, Facebook, Amazon, Big Oil, Boeing, ...

    Investors Business Daily
  6. 5 Big Drugmakers Reporting Earnings Next Week

    Investors Business Daily
  7. Ken Fisher's Best Investments: Credicorp, Ambev, Tata Motors

    GuruFocus
  8. Bristol-Myers Looks To A Promising Future

    Benzinga
  9. Barron's Picks And Pans: Bristol-Myers Squibb, KeyCorp, Core-Mark ...

    Benzinga
  10. Intercept Pharma Spikes On Report That It’s Exploring A Sale

    IBD
  11. Earnings Recap For January 28

    Benzinga
  12. Bristol Myers Ticks Higher Following Q4 Beat, Encouraging Guidance

    Benzinga
  13. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus
  14. JNJ Kicks Off Health Care Earnings—What About Deals, Buybacks?

    Benzinga
  15. Stock Marquee Crowded With Oil, Apple, and the Fed

    Benzinga
  16. Benzinga's Top Downgrades

    Benzinga
  17. Bristol-Myers Squibb's Opdivo + Yervoy Receives Expanded FDA ...

    Benzinga
  18. Benzinga's Top Upgrades

    Benzinga
  19. Fast Money Traders Share Their Biotech Picks

    Benzinga
  20. Dual Therapeutics Announces Oncology Strategic Collaboration ...

    GuruFocus
  21. Mylan, Momenta Team Up To Develop Biosimilar Drugs

    IBD
  22. 3 Potential Blockbuster Drugs Launching in 2016

    IBD
  23. Lilly Guidance Misses Estimates On Lower Sales

    IBD
  24. Baxalta Cuts Cancer Deal As Shire Circles Nearer

    IBD
  25. 5 Top Stocks of the Outperforming Vanguard Health Care Fund

    GuruFocus
  26. Glaxo's ViiV Acquiring Bristol-Myers' HIV Candidates

    IBD
  27. Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare ...

    Benzinga
  28. Strategic Beta ETFs Among Year's Top Performers

    IBD
  29. Fast Money Picks For December 15

    Benzinga
  30. Signature Select Sells Stake in SPDR Gold Trust

    GuruFocus
  31. Bristol-Myers Squibb CompanyNew Longer-Term Data for Empliciti ...

    Benzinga
  32. Amgen Expands Work With Merck, Files Biosimilar In EU

    IBD
  33. Bristol-Myers Squibb's

    IBD
  34. Bristol-Myers Plans Projects

    IBD
  35. Bristol-Myers Looks Beyond Cancer To Build Portfolio

    IBD
  36. Bristol-Myers Squibb Announces U.S. Food and Drug Administration ...

    Benzinga
  37. Goldman Sachs' Top 4 Smid-Cap Biotech Picks

    IBD
  38. Gilead Seen Staying Top Dog In HCV, But Merck Rising

    IBD
  39. BRISTOL-MYERS SQUIBB'S

    IBD
  40. Pamela Anderson And Hepatitis C: Which Drug Makers Are Working ...

    Benzinga
  41. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD
  42. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD
  43. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  44. How This Top Stock Mutual Fund Manager Seeks Growth

    IBD
  45. Bristol-Myers Squibb

    IBD
  46. Gilead Outlook Disappoints

    IBD
  47. 4 Drugmakers Who Beat Q3 Estimates Tuesday

    IBD
  48. These Three Pharma Giants Just Crushed Earnings

    Benzinga
  49. Earnings Scheduled For October 27, 2015

    Benzinga
  50. Earnings Boom This Week: Big Pharma, E-Commerce Giant BABA And ...

    Benzinga
  51. Fed Meeting A Mid-Week Bump In Flurry Of Earnings News

    Benzinga
  52. Eli Lilly Q3 Earnings, Guidance Beat On Cost Control

    IBD
  53. Bristol-Myers Squibb Says NICE Recommends Daklinza for Treatment ...

    Benzinga
  54. Mid-Afternoon Market Update: Dow Jumps 175 Points; Garmin Shares ...

    Benzinga
  55. Mid-Day Market Update: Crude Oil Down 2%; Five Prime Therapeutics ...

    Benzinga
  56. Benzinga's Volume Movers

    Benzinga
  57. Mid-Morning Market Update: Markets Rise; Citigroup Profit Tops ...

    Benzinga
  58. Morning Market Gainers

    Benzinga
  59. Benzinga's Top #PreMarket Gainers

    Benzinga
  60. Bristol-Myers Squibb, Five Prime Therapeutics Announce Worldwide ...

    Benzinga
  61. Five Prime Therapeutics to Host Conference Call on Worldwide ...

    Benzinga
  62. Bristol-Myers drug approved

    IBD
  63. Bristol-Myers' Opdivo Gets Another Early Approval

    IBD
  64. Full SEC Comments Regarding Bristol-Myers Squibb FCPA Violations

    Benzinga
  65. Facebook, Netflix Top Goldman Sachs' 2016 Growth List

    IBD
  66. Alexion, Vertex Steal Mo Stanley's Eyes From Gilead

    IBD
  67. Fast Money Picks For October 2

    Benzinga
  68. Bristol-Myers Squibb Receives Approval from the U.S. Food and ...

    Benzinga
  69. 3 Big Drugs Likely To Hit The Market Soon

    IBD
  70. Bristol-Myers, J&J Upgraded On New Drug Prospects

    IBD
  71. Benzinga's Top Upgrades

    Benzinga
  72. Yahoo PT Cut Despite Alibaba; McDonald's Upgraded

    IBD
  73. Wall Street Ends Mixed After Seesaw Session

    FoxBusiness
  74. Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in ...

    Benzinga
  75. Arrowhead Hits Target In Hepatitis B Drug Trial

    IBD
  76. Fast Money Picks For September 21

    Benzinga
  77. Make The World A Better Place With...Stock Picks?

    Benzinga
  78. Jim Cramer Shares His Thoughts On Home Depot, Bristol-Myers Squibb, ...

    Benzinga
  79. Amgen And Biogen Lead Short Interest Surge In Biotechs

    Benzinga
  80. Designing the Appropriate Common Stock Retirement Portfolio: ...

    GuruFocus
  81. Fast Money Picks For September 10

    Benzinga
  82. Mike Khouw Sees Unusual Options Activity In Bristol-Myers Squibb

    Benzinga
  83. BMY Announces CheckMate -017, -063 Trials Evaluating Opdivo in ...

    Benzinga
  84. BMY Announces Opdivo+Yervoy Dosing Schedules Showed Acceptable ...

    Benzinga
  85. Bristol-Myers Squibb to Host Investor Teleconference to Discuss ...

    Benzinga
  86. U.S. Food and Drug Administration Accepts for Priority Review ...

    Benzinga
  87. Benzinga's M&A Chatter for Thursday August 27, 2015

    Benzinga
  88. Allied-Bristol Life Sciences Licenses Platform Technology and ...

    Benzinga
  89. Weekly Insider Sells Highlight: IMS, NOW, BMY, EA

    GuruFocus
  90. uniQure Receives Additional $53M from Bristol-Myers Squibb for ...

    Benzinga
  91. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  92. Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal

    IBD
  93. Biogen's Big-Volume Plunge Marks End Of 5-Year Run

    IBD
  94. Valeant Posts Princely Gains

    IBD
  95. Bristol-Myers Q2 profit jumps

    IBD
  96. 3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates

    IBD
  97. Shire Lifts 2015 Guidance On Strong Drug Pipeline

    IBD
  98. Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance

    IBD
  99. Valeant Earnings Soar On M&A, Organic Sales Growth

    IBD
  100. Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast

    Benzinga
Trading Center